Literature DB >> 3971844

Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion.

J J Bending, J C Pickup, A C Collins, H Keen.   

Abstract

We assessed the quality of overnight glycemic control and the frequency of the "dawn phenomenon" (nadir-0800 h glycemic increase) in 41 insulin-dependent diabetic patients treated by continuous subcutaneous insulin infusion (CSII). Mean plasma glucose levels were near-normal during the 24 h and, in particular, constant throughout the night. In a subset of six patients overnight plasma free insulin concentrations were also constant during CSII. The majority of profiles (88%) showed a glucose nadir from 2.0 to 5.9 mmol/L (most frequently at 0600 h) and had an 0800 h value from 2.0 to 6.9 mmol/L (92%). A large proportion (46%) of profiles showed a zero or negative nadir-0800 h glycemic increase. In 22 patients with three or more profiles recorded at the same basal insulin infusion rate, only one of 103 profiles had a fasting glycemic increase greater than an arbitrary value of 5.0 mmol/L (5.3), although many patients exhibited small dawn glycemic increases (e.g., 14 of 22 had a mean increase of from 0 to 2 mmol/L). In 12 subjects a 15% reduction in basal insulin infusion rate increased the mean +/- SEM dawn glycemic increase from 0.58 +/- 0.25 mmol/L to 2.7 +/- 0.76 mmol/L (P less than 0.025) as well as significantly increasing the nocturnal nadir and 0800 h plasma glucose concentrations. Thus, a marked dawn phenomenon is rare when a single but adequate basal infusion rate is used for CSII, and this questions the need in the majority of patients for preprogrammable pumps with nocturnal infusion rate changes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971844     DOI: 10.2337/diacare.8.1.28

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia--evidence for the importance of beta-adrenergic stimulation.

Authors:  S Attvall; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

2.  The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity.

Authors:  G Perriello; P De Feo; E Torlone; C Fanelli; F Santeusanio; P Brunetti; G B Bolli
Journal:  Diabetologia       Date:  1991-01       Impact factor: 10.122

3.  Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning.

Authors:  G Perriello; P De Feo; E Torlone; C Fanelli; F Santeusanio; P Brunetti; G B Bolli
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

4.  Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.

Authors:  C G Fanelli; P De Feo; F Porcellati; G Perriello; E Torlone; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.

Authors:  C Fanelli; A Di Vincenzo; F Modarelli; M Lepore; M Ciofetta; L Epifano; S Pampanelli; P Brunetti; G B Bolli
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

6.  Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation.

Authors:  S Attvall; B M Eriksson; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

Authors:  Geremia B Bolli; David Kerr; Reena Thomas; Elisabetta Torlone; Agnès Sola-Gazagnes; Ester Vitacolonna; Jean Louis Selam; Philip D Home
Journal:  Diabetes Care       Date:  2009-04-23       Impact factor: 17.152

8.  Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes.

Authors:  Francesca Porcellati; Paola Lucidi; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes Care       Date:  2013-12       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.